TABLE 1.

Characteristics of 17 adult patients with proven, probable, or possible IA

Patient no.Age (yr)GenderaSCTPrimary disease or risk factorbIA classificationcDays posttransplantationGvHDNeutropenia (<0.5 × 109/liter)Chemotherapy during the preceding 4 wksSteroid use (>1 mg/ kg/day) during the preceding 3 wksOutcome at 3 mo after diagnosis
151FAllogeneicAMLProbable21NoYesYesNoSurvival
268FNoCLLProbableNoNoNoNoDeath
327MNoAMLProbableNoYesYesNoDeath
455MAllogeneicMyelomaProbable70YesYesNoYesDeath
531MAllogeneicAMLProbable28YesYesNoYesDeath
654FAllogeneicCLLProbable180YesYesNoYesDeath
769FNoCLLProbableNoYesYesNoSurvival
852FAllogeneicAMLProbable124YesYesNoNoSurvival
956MAllogeneicAplasiaProbableYesYesNoYesDeath
1034MNoAMLProbableNoYesYesNoSurvival
1177FNoALLProbableNoYesYesNoDeath
1253FNoMyelomaProbableNoYesYesNoDeath
1379MNoALLProbableNoNoNoNoDeath
1457FAllogeneicCLLProven340YesNoNoYesDeath
1563MNoAMLProbableNoYesYesNoDeath
1647MNoAMLPossibleNoYesYesNoSurvival
1718FAllogeneicAMLPossible150NoYesYesYesDeath
  • a M, male; F, female.

  • b ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphoid leukemia.

  • c According to European Organization for Research and Treatment of Cancer criteria. Criteria are from Ascioglu et al. (2).